Prolong Pharmaceuticals this month put its work in developing hemoglobin-based treatments into a new, higher orbit by tapping $2 million in grants.SOUTH BRUNSWICK Â Visitors to biotech serial ...
SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--Prolong Pharmaceuticals, LLC (the Company), a clinical-stage biopharmaceutical company, announced that it will present new clinical data from HEMERA-1 (Phase 1 ...
SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--Prolong Pharmaceuticals, LLC (the Company), a clinical-stage biopharmaceutical company, announced that the Company will deliver two oral presentations, an oral ...
PP-007 is a unique combination of a carbon monoxide releasing molecule and an oxygen transfer agent. The Food and Drug Administration (FDA) has granted Fast Track designation to PP-007 (PEGylated ...
Prolong Pharmaceuticals, LLC, a biopharmaceutical company dedicated to developing products for the treatment of anemias, cancers and their debilitating comorbidities, announced today that the U.S.
Don't mistake Prolong Pharmaceuticals LLC's lead program Sanguinate for a blood substitute. That term is a misnomer anyway, said Glenn Kazo, president of the South Plainfield, N.J.-based firm, since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results